William Chou has served as our Chief Executive Officer and member of the Board of Directors since October 2022. Dr. Chou is an accomplished executive with nearly 20 years of healthcare experience across a range of development and commercialization roles. Dr. Chou previously served as CEO of Aruvant Sciences, a clinical-stage biopharmaceutical company focused on developing gene therapies for rare disease. Prior to joining Aruvant, Dr. Chou served in a variety of leadership roles at Novartis, including Vice President and Global Disease Lead for Novartis’ Cell and Gene Therapy where he oversaw the global commercial launch of Kymriah®, the first CAR-T cell therapy. Prior to that role, Dr. Chou led the Kymriah® lymphoma clinical development program to approvals in the United States, Europe, Australia, Canada and Japan. Before joining Novartis, Dr. Chou worked at the Boston Consulting Group where he focused on commercial and clinical pharmaceutical strategy. Dr. Chou holds an MBA from the Yale School of Management, an MD from the University of Pittsburgh School of Medicine, and an AB in politics and economics from Princeton University. Dr. Chou completed his residency in internal medicine at Yale New Haven Hospital and his fellowship in geriatrics at Yale University.

Alex Fotopoulos, MSc, MBA, has served as our Chief Technical Officer since July 2019. From November 2017 to July 2019, Mr. Fotopoulos served as Senior Vice President, Technical Operations, Gene Therapy of Ultragenyx Pharmaceutical Inc., a biopharmaceutical company. From May 2016 to November 2017, Mr. Fotopoulos served as Senior Vice President, Technical Operations of Dimension Therapeutics, Inc., a biotechnology company, acquired by Ultragenyx Pharmaceutical Inc., focusing on the development of gene therapy for rare diseases associated with the liver and caused by genetic mutations. From August 2011 to May 2016, Mr. Fotopoulos served in various senior leadership roles at Momenta Pharmaceuticals, Inc., a biotechnology company, including Vice President, Technical Operations and Senior Director, Technical Operations. Prior to that, Mr. Fotopoulos served for 18 years in various senior leadership roles at Biogen, Inc., a biotechnology company, including Senior Director, Global Manufacturing Engineering and Director, Global Engineering Technology. Mr. Fotopoulos received a Diploma in Chemical Engineering at the National Technical University of Athens, Greece, an MSc in Chemical Engineering from Tufts University, and an MBA in General Management from the F.W. Olin Graduate School of Business at Babson College.

Simona King has served as our Chief Financial Officer since August 2021. She has more than 20 years’ strategic finance experience in the pharmaceutical and biotech industry, with both large and small companies. Her experience ranges from counseling executive teams on growth strategies to managing equity and debt financing to launching blockbuster products. She joins Passage Bio from Tmunity Therapeutics, where she served as CFO. Prior to that she was at Emergent BioSolutions as vice president of financial planning, analysis and assistant treasurer. Before Emergent, she worked for 19 years at Bristol Myers Squibb, holding a number of finance roles of increasing responsibility across most functional aspects of the organization, including mergers and acquisitions, R&D, commercial and manufacturing, eventually leading the company’s global financial processes as executive director of corporate financial planning and analysis. Ms. King is a certified public accountant. She earned her BA in economics at Kalamazoo College, and her MBA in finance from Columbia Business School. She also has a diploma in African Studies from the University of Cape Town, where she attended as a Rotary Ambassadorial Scholar.

Mark Forman has served as our Chief Medical Officer since July 2021. Before joining Passage Bio, he led the ADDF Scientific Affairs team that oversees the drug discovery and drug development portfolio. Dr. Forman is a neuropathologist and neuroscientist who, prior to joining ADDF, was vice president at Acadia Pharmaceuticals, where he was head of translational medicine, responsible for preclinical and early clinical development and contributed to development of pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis. Dr. Forman also spent 12 years at Merck where he was executive director and neuroscience lead in translational medicine, responsible for the neuroscience portfolio in early clinical development including contributions to the development of more than 20 novel therapeutics and multiple New Drug Applications. Dr. Forman has been a member of scientific advisory board for Biomarkers and Treat FTD at the Association for Frontotemporal Dementia since 2012. Dr. Forman received his PhD at Rockefeller University, MD at Duke University and BS at Yale University.

Edgar B. (Chip) Cale, has served as our General Counsel since September 2019 and Corporate Secretary since December 2019. From June 1998 to July 2019, Mr. Cale served in various senior leadership roles at GlaxoSmithKline plc, a multinational pharmaceutical company, including Senior Vice President, Legal Corporate Functions; Vice President, Associate General Counsel, Legal Operations, WWBD; Vice President, General Counsel, GSK Vaccines; and Assistant General Counsel. Prior to that, Mr. Cale served as a corporate and securities lawyer supporting emerging growth companies in the life science and technology industries at Venture Law Group LLP and Brobeck, Phleger & Harrison LLP. Mr. Cale received a BS in Biology from the University of Pennsylvania and a JD from the University of California, Berkeley.

James M. Wilson, MD, PhD, is the Director of the Gene Therapy Program; Rose H. Weiss Professor and Director of the Orphan Disease Center and Professor of Medicine and Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. Dr. Wilson serves as Chief Scientific Advisor at Passage Bio. Dr. Wilson’s laboratory has made seminal contributions to the technology of gene transfer and has paved the way for translation of these technologies into the clinic. He has published over 550 papers and is named on over 110 patents. After launching his faculty career in the Howard Hughes Medical Institute at the University of Michigan, he moved to the University of Pennsylvania in 1993. Dr. Wilson completed his training in Internal Medicine at the Massachusetts General Hospital followed by a postdoctoral fellowship at the Whitehead Institute, where he began his work in gene therapy.

Maxine Gowen, Ph.D., has served as a member of Passage Bio’s board of directors since Feb. 2021 and was appointed chairwoman in August 2021. Dr. Gowen is chief executive officer of Tamuro Bio, a role that she has held since July 2019. Prior to Tamuro Bio, she was the founding president and chief executive officer of Trevena, Inc. from 2007 to October 2018. Previously she held a variety of leadership roles at GlaxoSmithKline, GSK, over a period of 15 years. As senior vice president for GSK’s Center of Excellence for Drug Discovery, she developed an innovative new approach to externalizing drug discovery. She also currently serves on the boards of directors for Aclaris Therapeutics, Inc., Idera Pharmaceuticals, Inc., Merus N.V., and the private company Tamuro Bio. Dr. Gowen graduated with a BSc in biochemistry from the University of Bristol, UK, received a PhD in cell biology from the University of Sheffield, UK, and received an MBA from the Wharton School of the University of Pennsylvania. We believe Dr. Gowen is qualified to serve as chairwoman of our board of directors due to her deep biopharmaceutical industry experience in research and development, as a board member and CEO.

Athena Countouriotis, MD, has served as a member of our board of directors since February 2020. Dr. Countouriotis has also served as Chief Executive Officer and a member of the board of directors of Turning Point Therapeutics Inc. since October 2018, and from May 2018 to September 2018, she served as Chief Medical Officer of Turning Point Therapeutics. Dr. Countouriotis served as Senior Vice President and Chief Medical Officer for Adverum Biotechnologies, Inc. from June 2017 to May 2018, and before that served as Senior Vice President, Chief Medical Officer of Halozyme Therapeutics, Inc. from January 2015 to May 2017. Dr. Countouriotis also served as Chief Medical Officer of Ambit Biosciences Corporation from February 2012 until Ambit's acquisition by Daiichi Sankyo Company in November 2014. Earlier in her career, Dr. Countouriotis led various clinical development organizations within Pfizer Inc. and Bristol-Myers Squibb Company for oncology therapeutics. Dr. Countouriotis currently serves on the boards of directors of Iovance Biotherapeutics, Inc. and Trovagene, Inc., both public oncology therapeutics companies. Dr. Countouriotis earned a BS from the University of California, Los Angeles, and an MD from Tufts University School of Medicine. She received her initial training in pediatrics at the University of California, Los Angeles, and additional training at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology/Oncology Program. We believe that Dr. Countouriotis is qualified to serve on our board of directors due to her broad oncology biotech leadership experience and history of guiding multiple development programs to approval.

Derrell D. Porter, MD, has served as a member of Passage Bio’s board of directors since May 2021. Dr. Porter is founder and chief executive officer of Cellevolve Bio, Inc. Prior to founding and leading Cellevolve Bio in 2020, Dr. Porter served as senior vice president and head of Commercial at Atara Biotherapeutics, Inc. from May 2017 to October 2019. While there, he built the global commercial organization, including its product launch strategy. Prior to joining Atara, Dr. Porter served as a vice president with Gilead Sciences from April 2013 to May 2017, where he was responsible for corporate strategy, commercial planning, and global launch preparation for all of Gilead’s therapeutic areas. Previously, Dr. Porter was at AbbVie and Amgen, where he served in multiple US, EU and global roles of increasing responsibility in strategy, corporate development, business unit management, and sales and marketing. Dr. Porter began his career at McKinsey & Company in Los Angeles as part of the West Coast Health Care Practice. He currently serves on the boards of directors of several private companies. Dr. Porter holds an MD and an MBA from the University of Pennsylvania, and a bachelor’s degree in psychobiology / neuroscience from the University of California, Los Angeles. We believe Dr. Porter is qualified to serve on our board of directors due to his strong corporate strategy, product development and commercial experience.

Michael Kamarck, PhD, has served as a member of Passage Bio’s board of directors since July 2022. Dr. Kamarck is the Chairman of the Sanofi Biotech Advisory Council, providing strategic guidance to advance Sanofi’s biologicals business. He recently retired as Chief Technology Officer for Vir Biotechnology, Inc., where he led a multi-modality technical approach to the development of treatments of serious infectious diseases such as COVID-19 (sotrovimab), influenza and hepatitis B. Prior to joining Vir, Dr. Kamarck was the Senior Vice President of Global Vaccines and Biologics Manufacturing and President of Merck BioVentures. In this role, he was responsible for the worldwide manufacturing network in support of the vaccine portfolio and biologics businesses. Dr. Kamarck also held numerous senior executive positions at Wyeth Pharmaceuticals, including President, Technical Operations and Product Supply as a member of the Wyeth Management Team. While with Wyeth, he was responsible for establishing a global biotechnology network of more than 10,000 employees to develop and manufacture numerous blockbuster products, including building the manufacturing infrastructure to deliver the global supply of Prevnar 13® and Enbrel®. Dr. Kamarck also spent 16 years at Bayer AG serving in numerous roles, including Senior Vice President of Operations for Bayer Biologicals. He has authored more than 50 peer-reviewed publications and has 20 issued patents. He currently serves on the board of directors of Vaxcyte, Inc. Dr. Kamarck holds a Ph.D. in biochemistry from the Massachusetts Institute of Technology and a bachelor’s degree in biology from Oberlin College. We believe that Dr. Kamarck is qualified to serve on our board of directors due to his extensive expertise and leadership in biopharmaceutical product development and manufacturing.

Sandip Kapadia has served as member of our board of directors since December 2019. Mr. Kapadia brings over 25 years of science industry experience and has served as the Chief Financial Officer (CFO) for Harmony Biosciences since March 2021. Previously Mr. Kapadia was CFO for Intercept Pharmaceuticals. Before Intercept, Mr. Kapadia served in various leadership capacities within finance for more than 19 years at Novartis International AG and Novartis affiliates in the United Kingdom, Netherlands, Switzerland and the US. Mr. Kapadia received a BS in Accounting from Montclair State University and an MBA from Rutgers University, and is also a US Certified Public Accountant. Mr. Kapadia currently serves on the boards of directors of Molecular Partners AG and VectivBio Holding AG. We believe that Mr. Kapadia is qualified to serve on our board of directors due to his leadership experience in the biopharmaceutical industry and finance expertise.

Saqib Islam has served as a member of our board of directors since March 2019. Mr. Islam has also served as Chief Executive Officer and a member of the board of directors of SpringWorks Therapeutics, Inc., a biopharmaceutical company, since August 2018, and from August 2017 to August 2018, he served as Chief Financial Officer and Chief Business Officer of SpringWorks. From February 2016 to August 2017, Mr. Islam served as Chief Business Officer at Moderna Therapeutics, Inc., a biotechnology company. From February 2013 to February 2016, Mr. Islam served as Executive Vice President, Chief Strategy and Portfolio Officer at Alexion Pharmaceuticals, Inc., a pharmaceutical company. Prior to joining Alexion, Mr. Islam worked for more than 25 years in international business management with a focus on business development, strategic decision-making and planning and capital markets, previously holding managing director positions at Morgan Stanley and Credit Suisse. Mr. Islam received a BA in Commerce from McGill University and a JD from Columbia Law School. We believe that Mr. Islam is qualified to serve on our board of directors due to his experience and expertise in operations management and executive leadership at various biopharmaceutical and biotechnology companies.

Thomas Woiwode, PhD, has served as a member of our board of directors since September 2018. Since 2002, Dr. Woiwode has served in various investment and operational roles at Versant Venture Management, LLC, a healthcare investment firm, including Managing Director since July 2014 and a Venture Partner from 2011 to 2014. From 2011 to 2013, Dr. Woiwode served as Chief Operating Officer of Okarios AG, a biopharmaceutical company. Previously, Dr. Woiwode co-founded EuroVentures, a wholly owned biotechnology incubator within Versant Venture Management, LLC, and in this role, served as the founding Chief Business Officer for three biotechnology portfolio companies. Prior to Versant, Dr. Woiwode served as a Research Scientist at XenoPort, Inc., a biotechnology company. Dr. Woiwode currently serves on the boards of directors of Gritstone Oncology, Inc. and Adverum Biotechnologies, Inc., as well as several private companies. Dr. Woiwode previously served on the board of directors of Audentes Therapeutics, Inc. and Crispr Therapeutics AG, both public biotechnology companies. Dr. Woiwode received a BA in English and a BS in Chemistry from the University of California, Berkeley and a PhD in Organic Chemistry as an NSF Fellow from Stanford University. We believe that Dr. Woiwode is qualified to serve on our board of directors due to his educational background, experience as a board member and senior executive of biotechnology and pharmaceutical companies, and experience as an investor in new life sciences companies.